Seosan hits the 30% limit for a second day, and no filing explains it
KOSPI fell 5.46% on Oct. 13, yet Seosan (079650) rose 29.88% with no DART filing and no company news. HLB Biostep (278650) gained 12.05% on a reported state project and Kukje Pharma (002720) 17.33% in a rebound tied to a family succession.
Seoul — On Oct. 13, KOSPI (Korea's main market) closed down 5.46% at 6035.35 and KOSDAQ (the tech- and small-cap-heavy market) fell 1.43% to 837.03, yet three stocks rose more than 10%. Seosan (079650) hit the 30% daily limit for the second day in a row with no filing from the company and no company-related news. HLB Biostep (278650) rose on a report about a state-funded project and Kukje Pharma (002720) on a family succession story, but no filing directly explains today's gain in any of the three.
At a glance
| Stock | Why it rose | Nature of the news | Evidence | What to check next |
|---|---|---|---|---|
| Seosan (079650) 8,780 won, +29.88% | No reason found | No reason | None (no filings in 7 days) | A company explanation or filing; whether foreign net buying continues |
| HLB Biostep (278650) 5,950 won, +12.05% | Reported participation in a 5 billion won AI state project | Expectation | Press only (the only filing is an IR event notice) | Whether the company states the project's size and period itself |
| Kukje Pharma (002720) 4,570 won, +17.33% | Rebound after a pullback from the Oct. 7 limit-up; owner's son taking over shares | Expectation | Filing confirmed (change of largest shareholder etc., share transfer only) | A filing on the holding company's shares; whether the profit decline stops |
Seosan: second straight limit-up, and no reason has surfaced
No reason for Seosan's rise has surfaced. It closed up 29.88% at 8,780 won, the 30% daily limit, after the same move on Oct. 12, gaining 67.9% in two days and 55.7% in five. DART (Korea's official disclosure system) shows no filings in the past seven days, including no insider holding reports. Today's articles containing 'Seosan' are about the city: an apartment fire (Newsis) and park golf courses (Seoul Shinmun).
The one visible footprint is foreign net buying. Foreigners were net buyers for four sessions through Oct. 12, about 289,000 shares in total, and on Oct. 12 they bought about 107,000 shares while individuals sold about 155,000. Institutions barely moved. Why foreigners bought is not stated anywhere. The 8,780 won close is the highest since Sept. 3 (the previous high was 8,040 won on Sept. 10), reached three sessions after a 5,230 won close on Oct. 8. Trading value of 88.1 billion won is about half of the 175.6 billion won market cap. We rated it 'press only' on Oct. 12, but no company-related article appeared today.
To judge whether this holds, watch whether the company explains the move through a disclosure or an exchange inquiry reply, and whether foreign net buying continued once Oct. 13 flows are published. The 5,230 won close on Oct. 8 shows how far the price can fall back.
HLB Biostep: up 12% on a 5 billion won AI project report, with no filing on it
HLB Biostep rose after morning reports that it will take part in a 5 billion won state project called 'AI-NAMs' to predict the immune response of biologic drugs with AI. Medical Today (10:18 a.m.), Pinpoint News, Daily Pharm and Etoday ran the same story, and Etoday's headline framed it as aiming at a 'digital non-clinical CRO' (contract research organization). On DART, the only filing in the past week is an investor relations (IR) event notice on Oct. 12, and its title alone does not show whether it relates to the project. The project itself is not confirmed by a company filing.
The 5 billion won is 4.8% of the 103.7 billion won market cap. The stock, meanwhile, rose from 2,885 to 6,310 won over three straight limit-up days on Oct. 6-8, fell 15.85% on Oct. 12 and gained 12.05% today, still 5.7% below the Oct. 8 close. Counting only the price change, the market cap added about 53 billion won in a week, more than ten times the project size. CBC News reported four volatility interruptions (VI, brief trading pauses on sharp moves) in the morning. The stock was up 19.21% around 1:30 p.m. and closed at 12.05%. Trading value was 39.0 billion won.
Two things to check: whether the company confirms the project in a filing or IR material with its own share of the amount and period, and whether trading value holds near today's 39.0 billion won the next day.
Kukje Pharma: 17% rebound after a pullback, with a succession story in the background
No new news came out today. The price rebounded after falling on Oct. 8 and Oct. 12 following the Oct. 7 limit-up; Namdo Ilbo described it as a 'rebound after correction.' The 4,570 won close is above the 4,430 won close of Oct. 7. The backdrop is last week's filings on a share transfer within the owner family. DART shows a change of largest shareholder and a report on shareholding changes on Oct. 6, a large-holding report by Nam Young-woo on Oct. 7, and insider ownership reports by Nam Tae-hoon and Nam Young-woo on Oct. 8. The Fact reported that Vice Chairman Nam Tae-hoon took over all of his father, Honorary Chairman Nam Young-woo's, direct shares and now holds 10.7%.
A gift of shares, though, changes who owns the company and brings in no cash or sales. The same report said first-half operating profit fell 29.4% and that a 55.5 billion won facility investment weighs on the company. The largest shareholder side's stake stayed at 37.95% (CBC News). On Oct. 8 foreigners sold more than 610,000 shares net while individuals bought nearly 630,000. Today's trading value of 144.2 billion won is about 1.5 times the 96.7 billion won market cap.
The Fact also said the transfer of the holding company Woogyung's shares has not been decided. Whether that transfer shows up in a filing, and whether operating profit stops falling in the next earnings report, will show whether succession or earnings is driving the stock. Whether trading value holds near yesterday's level is the other thing to watch.
How earlier picks did
| Stock | Verdict then | Close on article date | Close on Oct. 13 | Change |
|---|---|---|---|---|
| Seosan | Press only | 6,760 won (Oct. 12) | 8,780 won | +29.9% |
| RaonSecure | Press only | 14,870 won (Oct. 6) | 17,270 won | +16.1% |
| Kumho Electric | Press only | 11,070 won (Oct. 12) | 11,530 won | +4.2% |
| Samki Energy Solutions | Press only | 2,305 won (Oct. 8) | 2,250 won | -2.4% |
| HLB Biostep | Press only | 6,310 won (Oct. 8) | 5,950 won | -5.7% |
| Kumho E&C | Press only | 13,430 won (Oct. 12) | 12,070 won | -10.1% |
| HLB Global | Press only | 2,635 won (Oct. 8) | 2,175 won | -17.5% |
| Sandslab | Press only | 8,970 won (Oct. 6) | 7,360 won | -17.9% |
All eight were rated 'press only' at the time; three are higher and five lower. Even allowing for a day when KOSPI fell 5.46%, two of the press-only rallies have since given back more than 17%.
FAQ
Why did Seosan stock go up?
No reason found. Evidence: None (no filings in 7 days). What to check next: A company explanation or filing; whether foreign net buying continues.
Why did HLB Biostep stock go up?
Reported participation in a 5 billion won AI state project. Evidence: Press only (the only filing is an IR event notice). What to check next: Whether the company states the project's size and period itself.
Why did Kukje Pharma stock go up?
Rebound after a pullback from the Oct. 7 limit-up; owner's son taking over shares. Evidence: Filing confirmed (change of largest shareholder etc., share transfer only). What to check next: A filing on the holding company's shares; whether the profit decline stops.